Botulinum Toxin Compositions

Botulinum toxin compositions with unconjugated botulinum toxin and specific excipients address the challenge of reduced diffusion and prolonged efficacy, enhancing therapeutic outcomes and patient convenience.

JP2024543080APending Publication Date: 2024-11-19MEDY TOX INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024528620
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-11
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing botulinum toxin compositions without animal proteins lack effective methods to prolong their therapeutic effects and reduce diffusion, leading to potential side effects and reduced efficacy.

Method used

Development of botulinum toxin compositions containing unconjugated botulinum toxin as an active ingredient, free from animal proteins, with specific excipients to enhance therapeutic efficacy and reduce diffusion.

Benefits of technology

The compositions exhibit prolonged therapeutic effects, reduced diffusion, and improved patient convenience by minimizing side effects, with enhanced muscle action potential maintenance at the administration site.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543080000001_ABST
    Figure 2024543080000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to botulinum toxin compositions that have reduced diffusion effects and / or are effective for an extended period of time.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to botulinum toxin compositions. [Background technology]

[0002] Botulinum toxin (BoNT) is a polypeptide product of the anaerobic Clostridium botulinum, which prevents the secretion of neurotransmitters at the interface between nerves and muscles, thereby paralyzing muscles. Although botulinum toxin is a toxic substance that is originally lethal, it was first used for diseases caused by excessive muscle contraction, including the treatment of strabismus, and its range of use has expanded and it is now used for a variety of purposes. Botulinum toxin is mainly used to treat muscle tone disorders and other non-muscle tone disorder movement disorders, such as hemifacial spasm, tremor, and spasticity. In addition, it is used for a variety of indications, such as ocular diseases, pain-related diseases such as migraines, urologic diseases, and cosmetic wrinkle treatment.

[0003] Korean Publication KR2016-0113597 relates to an animal protein-free botulinum toxin composition and its use in patients in need of treatment for a disease, disorder or abnormality, and discloses that the animal protein-free botulinum toxin composition has a longer effect of botulinum toxin than a botulinum toxin composition containing animal protein.

[0004] However, to date, there are no known botulinum toxin compositions that have a reduced spreading effect.

[0005] Korean Publications KR2008-0050636 and KR2008-0049152 disclose pharmaceutical compositions composed of a botulinum neurotoxin or a mixture of a botulinum neurotoxin and a botulinum neurotoxin free of complex proteins naturally formed with the botulinum neurotoxin, respectively. Korean Publication KR2016-0113597 relates to an animal protein-free botulinum toxin composition and its use in patients in need of treatment for a disease, disorder or abnormality, and discloses that the animal protein-free botulinum toxin composition has a longer effect of the botulinum toxin than a botulinum toxin composition containing an animal protein.

[0006] However, there have been no attempts to date to extend the effectiveness of botulinum toxin compositions that contain uncomplexed botulinum toxin as the active ingredient and that do not contain animal protein. Summary of the Invention [Problem to be solved by the invention]

[0007] It is an object of the present invention to provide a botulinum toxin composition having a reduced diffusion effect, its use in treating a disease, or a method of administering it to a subject in need thereof to treat a disease.

[0008] It is an object of the present invention to provide a botulinum toxin composition comprising an uncomplexed botulinum toxin as an active ingredient and free of animal protein, its use in the manufacture of a medicament for the treatment of a disease, or a method of administering it to a subject in need thereof to treat a disease. [Means for solving the problem]

[0009] The present invention relates to botulinum toxin compositions that have reduced diffusion effects and / or are effective for an extended period of time. Effect of the Invention

[0010] According to one embodiment of the present invention, there is provided a botulinum toxin composition having a reduced diffusion effect and thereby reducing the risk of side effects due to diffusion, its use in the manufacture of a medicament for the treatment of a disease, and a method of treatment using the same.

[0011] According to the present disclosure, there are provided botulinum toxin compositions containing uncomplexed botulinum toxin as an active ingredient and free of animal protein, which have a prolonged effect, improved therapeutic efficacy, and improved patient convenience, their use in the manufacture of compositions for treating diseases, and treatment methods utilizing the same. [Brief description of the drawings]

[0012] [Figure 1] 1 is a graph showing compound muscle action potential (CMAP) values ​​for treated and contralateral untreated muscles 7 days after administration of two botulinum toxin type A products (Coretox, Neuronox) and placebo into the right calf muscle in mice described herein in Example 1. CMAP values ​​were analyzed using a two-tailed t-test. [Diagram 2] Figure 1 shows CMAP values ​​in the right tibialis anterior (treated muscle) and right calf muscle (untreated muscle) on day 14 after administration of two different formulations of complexed botulinum toxin type A (TFXA21004 (albumin formulation), NXA20001 (non-albumin formulation)) and placebo into the right tibialis anterior muscle in rats as described in Example 2 herein. CMAP values ​​were analyzed using a two-tailed t-test. [Diagram 3]FIG. 1 is a graph showing the change in DAS score over time following repeated administration of five botulinum toxin type A products (Coretox, Xeomin, Botox, Neuronox, Innotox) and a placebo three times into the right calf muscle in mice described in Example 3 herein. The arrows at the top of the graph indicate the time when each botulinum toxin type A product was administered. [Figure 4] FIG. 1 is a graph showing the time course of calf muscle CMAP values ​​at the injection site in mice as described in Example 3 herein, where five botulinum toxin type A products (Coretox, Xeomin, Botox, Neuronox, Innotox) and a placebo were repeatedly administered three times to the right calf muscle. The arrows at the top of the graph indicate the time when each botulinum toxin type A product was administered, and at the end of the study (252 days after the first injection), one-way ANOVA was performed on the CMAP values ​​of each botulinum toxin-administered group, followed by analysis using Tukey's post-hoc test for intergroup comparison. Different letters in a, b, and c indicate statistically significant differences. [Diagram 5] FIG. 1 is a graph showing CMAP values ​​of the contralateral calf muscle on days 6-7 after administration of five botulinum toxin type A products (Coretox, Xeomin, Botox, Neuronox, Innotox) and placebo three times into the right calf muscle in mice described in Example 3 herein. CMAP values ​​of the contralateral muscle for each botulinum toxin administration group were analyzed by one-way analysis of variance (one-way ANOVA) and Tukey's post-hoc test for between-group comparison. Different letters in a, b, and c indicate statistically significant differences. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly used in the field to which this disclosure belongs. For the understanding of this disclosure, the following definitions are applied, but the singular expression includes the plural expression and vice versa unless otherwise clearly indicated in the context.

[0014] As used herein, the term "botulinum toxin" refers to any botulinum toxin protein molecule, including any serotype, variant, or fusion protein thereof, whether bacterially or recombinantly produced.

[0015] In one embodiment, the botulinum toxin can be used without restriction on serotype and can be selected from the group consisting of type A (BoNT / A), type B (BoNT / B), type C (BoNT / C), type D (BoNT / D), type E (BoNT / E), type F (BoNT / F), type G (BoNT / G), type H (BoNT / H), type X (BoNT / X), Enterococcus species botulinum toxin J (eBoNT / J) and mosaic botulinum toxin, and / or variants thereof. Examples of mosaic toxins include BoNT / DC, BoNT / CD and BoNT / FA. For example, type A can be used.

[0016] In one embodiment, the botulinum toxin is derived from various BoNT / A subtypes, such as BoNT / A1, A2, A3, A4, A5, A6, A7, A9, A10; BoNT / B subtypes, such as BoNT / B1, B2, B3, B4, B5, B6, B7, B8, Bnp and Bbv; BoNT / C subtypes, such as BoNT / C and CD; BoNT / D subtypes, such as BoNT / D and DC; BoNT / E subtypes, such as BoNT / E1, E2, E3, E4, E5, E6, E7, E8, E9; BoNT / F subtypes, such as BoNT / F1, F2, F3, F4, F5, F6, F7; and BoNT / G subtypes, such as BoNT / subtype G. The BoNT subtypes include chimeric BoNTs, such as BoNT / DC, BoNT / CD, BoNT / FA, and the like.

[0017] Botulinum toxins include botulinum toxin derivatives. The botulinum toxin derivatives are also derivatives that contain one or more chemical or functional modifications on a portion or a portion of a chain of a natural or recombinant native botulinum toxin that has botulinum toxin activity. For example, the botulinum toxin derivatives are also modified toxins that have one or more amino acids deleted, modified or substituted. The botulinum toxins are also recombinant peptides, fusion proteins, or hybrid neurotoxins made, for example, from subunits or domains of different toxin serotypes. The botulinum toxins can also be part of an entire molecule that has toxic activity, or can be utilized as part of a combination or conjugated molecule, for example, a fusion protein.

[0018] The term "complex protein" refers to hemagglutinin and nontoxic nonhemagglutinin (NTNH), which does not have hemagglutinin activity.

[0019] Strains of Clostridium botulinum produce immunologically distinct neurotoxins (type AG). The molecular masses of type AG neurotoxins (NTX) are approximately 150 kDa (7S). In culture media and foods with acidic conditions, NTX binds to non-toxic components to form large complexes called progenitor toxins (PTX). PTX can have molecular masses of 900 kDa (19S), 500 kDa (16S) and 300 kDa (12S). The 12S toxin is composed of NTX and a non-toxic component that does not have hemagglutinin activity (NTNH), while the 19S and 16S toxins are composed of NTX, NTNH and hemagglutinin. Type A strains produce three forms of the toxin (19S, 16S and 12S), while types B, C and D strains produce 16S and 12S toxins. Under alkaline conditions, PTX is dissociated into NTX and non-toxic components, 19S and 16S toxins are dissociated into NTX, NTNH and the non-toxic components of hemagglutinin, and 12S toxin is dissociated into NTX and NTNH.

[0020] The botulinum toxin composition of the present invention may also be a complex botulinum toxin composition comprising a complex protein, for example, the complex botulinum toxin may comprise NTNH or hemagglutinin, in which case the molecular weight of the complex botulinum toxin may be about 900 kDa.

[0021] The botulinum toxin composition of the present invention may also be an uncomplexed botulinum toxin composition that does not contain a complexing protein, for example, the uncomplexed botulinum toxin may not contain NTNH or hemagglutinin, in which case the molecular weight of the uncomplexed botulinum toxin may be about 150 kDa.

[0022] The term "animal protein" refers to blood-derived, blood-contaminated, or other animal-derived products.

[0023] The botulinum toxin compositions of the present invention are also animal protein-free botulinum toxin compositions. For example, the botulinum toxin compositions of the present invention are also free of animal-derived protein stabilizers. In one embodiment, the botulinum toxin compositions of the present invention are also free of human serum albumin or recombinant human albumin.

[0024] The term "active ingredient" refers to a substance of a formulation or composition that is biologically or physiologically effective. In particular, in the context of a pharmaceutical formulation or composition, the term "active ingredient" refers to a component substance that exhibits a desired pharmacological effect. For example, the active ingredient of the present invention can be a botulinum toxin without complexing proteins.

[0025] "Administration" or "administering" refers to the step of providing a pharmaceutical composition or active pharmaceutical ingredient to a subject. The pharmaceutical composition can be administered via a variety of suitable routes.

[0026] In one embodiment, the pharmaceutical composition may be administered transdermally, subcutaneously, or intramuscularly. In one embodiment, the composition may be administered locally to a muscle or muscle group. For example, reduction of forehead wrinkles, skin wrinkles may be achieved by administering the composition transdermally or subcutaneously to the wrinkle. For example, the composition of one embodiment may be administered subcutaneously or intramuscularly. The composition of one embodiment may be administered subcutaneously or intramuscularly via a pre-filled syringe. The composition of one embodiment may be administered transdermally using a transdermal patch or microneedles.

[0027] "Pharmaceutical composition" refers to a formulation containing an active ingredient. "Pharmaceutical composition" also includes at least one further ingredient, such as albumin (human serum albumin or recombinant human albumin) and / or sodium chloride, in addition to the active ingredient (e.g., botulinum toxin). The pharmaceutical composition is a formulation suitable for administration to a subject, such as a mammal, including humans. The pharmaceutical composition can be in liquid form or lyophilized form. If the pharmaceutical composition is a lyophilized formulation, the lyophilized pharmaceutical composition can be used by redissolving it, for example, using saline or water. It can also be in solution form. The pharmaceutical composition can be liquid or solid. The pharmaceutical composition is free of animal-derived proteins and / or albumin.

[0028] "Treate", "treating" or "treatment" refers to the alleviation or reduction (including partial reduction, substantial reduction, nearly complete reduction, and complete reduction), resolution or prevention (both temporary and permanent) of a disease, disorder or condition, such as by healing injured or damaged tissue, or by altering, changing, enhancing, improving, improving and / or beautifying an existing or recognized disease, disorder or condition, to achieve a desired therapeutic result. As used herein, "treatment" is a concept that includes prevention. "Prevention" refers to delaying the onset of a disease, disorder or condition. Prevention can be considered complete if the onset of a disease, disorder or condition has been delayed for a predetermined period of time.

[0029] In one embodiment, "treatment" refers to the treatment of a disease, disorder or medical condition in a patient, such as a mammal (particularly a human), which includes one or more of the following: (a) preventing the occurrence of any of the aforementioned diseases, disorders or medical conditions, i.e. preventing the recurrence of any of the aforementioned diseases or medical conditions, or the prophylactic treatment of patients pre-disposed to any of the aforementioned diseases or medical conditions; (b) ameliorating, i.e., eliminating or causing regression of, said disease, disorder or medical condition in a patient, including antagonizing the effects of other therapeutic agents; (c) suppressing such a disease, disorder or medical condition, i.e., slowing or arresting the development of such a disease, disorder or medical condition in a patient; or (d) alleviating the symptoms of said disease, disorder or medical condition in a patient.

[0030] As used herein, the terms "unit", "unit(s)" or "U" refer to the LD50 dose, defined as the amount of botulinum toxin that killed 50% of mice injected with the botulinum toxin, and are used interchangeably within a product.

[0031] In one embodiment, the therapeutically effective amount of botulinum toxin is about 0.01 U / kg to about 100 U / kg, about 0.1 U / kg to about 100 U / kg, about 0.2 U / kg to about 100 U / kg, about 0.2 U / kg to about 50 U / kg, about 0.2 U / kg to about 30 U / kg, about 0.2 U / kg to about 10 U / kg, or about 0.2 U / kg to about 1 U / kg. In other embodiments, based on a 60 kg adult body weight, it is about 1 U to about 10,000 U, about 1 U to about 5,000 U, about 1 U to about 2,500 U, about 1 U to about 1,000 U, about 1 U to about 500 U, about 1 U to about 300 U, about 1 U to about 200 U, about 10 U to about 200 U, about 10 U to about 100 U, or about 10 U to about 50 U.

[0032] According to one embodiment of the invention, there is provided an animal protein-free botulinum toxin composition, which also includes a pharma- ceutically acceptable excipient or additive that is not derived from animal protein. In one embodiment, the composition is animal protein-free and includes a botulinum toxin as an active ingredient for use in a method for treating a disease in a patient in need of treatment, the method comprising the step of topically administering to a subject in need of treatment a therapeutically effective amount of the composition, which also has reduced diffusion at the site of administration compared to botulinum toxin compositions that include animal protein.

[0033] In one embodiment, the botulinum toxin is an uncomplexed botulinum toxin.

[0034] The compositions of one embodiment also have a more extended duration of effect at the site of administration than botulinum toxin compositions that include animal proteins.

[0035] In one embodiment, the pharma- ceutically acceptable excipient or additive is a stabilizer, an ionic compound, a surfactant, a buffering agent, a lyoprotectant, or a combination thereof, such as an amino acid (e.g., methionine), a salt (e.g., NaCl), a buffer solution, a non-ionic surfactant (e.g., a polysorbate, e.g., polysorbate 20), a sugar (e.g., a disaccharide such as sucrose), a sugar alcohol (e.g., sorbitol), or a combination thereof.

[0036] The botulinum toxin compositions of the present invention may be formulated in any form, such as a solid or liquid formulation, for example, a lyophilized powder, liquid, or pre-filled syringe formulation.

[0037] In one embodiment, the composition is a lyophilized composition. In one embodiment, the lyophilized composition includes a botulinum toxin, a non-ionic surfactant such as a polysorbate, and / or an amino acid, and also includes one or more components selected from the group consisting of sugars, sugar alcohols, and ionic compounds.

[0038] In one embodiment, the polysorbate may include, for example, polysorbate 20, 40, 60, 80, or 100, such as polysorbate 20. In one embodiment, the amino acid may be methionine or isoleucine. For example, one embodiment of the liquid composition may include polysorbate 20 and methionine as stabilizers.

[0039] In one embodiment, the sugar may include trehalose, sucrose, maltose, fructose, raffinose, lactose, or glucose. The sugar alcohol may include cyclodextrin, mannitol, sorbitol, glycerol, xylitol, or inositol. For example, the lyophilized composition of one embodiment may include white sugar (sucrose).

[0040] In one embodiment, the ionic compound may include sodium chloride, sodium phosphate, ammonium phosphate, magnesium sulfate, sodium acetate, sodium lactate, sodium succinate, sodium propionate, or potassium phosphate.

[0041] In one embodiment of the lyophilized composition, polysorbate may be present in an amount of 0.01 to 2 mg, methionine in an amount of 0.01 to 10 mg, sugar in an amount of 0.1 to 50 mg, sugar alcohol in an amount of 0.1 to 50 mg, and ionic compound in an amount of 0.1 to 10 mg per 100 units of botulinum toxin.

[0042] The composition of an embodiment is also a liquid composition. The liquid composition of an embodiment includes a botulinum toxin and a non-ionic surfactant, such as a polysorbate, and / or an amino acid. In an embodiment, the polysorbate includes, for example, polysorbate 20, 40, 60, 80, or 100, such as polysorbate 20. In an embodiment, the amino acid is methionine or isoleucine. For example, the liquid composition of an embodiment includes polysorbate 20 and methionine as stabilizers. In an embodiment, the concentration of the polysorbate is 0.05 to 2.5 mg / mL, or 0.1 to 2.5 mg / mL, and the concentration of the methionine is 0.5 to 50 mM, or 25 to 75 mM. The pH of the liquid composition of an embodiment is 5.5 to 7.0.

[0043] The reduced diffusion effect or extended duration effect of the composition of an embodiment may occur with repeated administration one or more times, two or more times, three or more times, four or more times, or five or more times. The compound muscle action potential measurement value of the muscle adjacent to the administration site muscle of the composition of an embodiment may also be higher than the compound muscle action potential measurement value of the muscle adjacent to the administration site muscle when the same dose of the animal protein-containing composition is administered to the same administration site and the same administration position. In this specification, the "muscle adjacent to the administration site muscle" means a muscle that is separated from the administration site muscle by a predetermined distance. In addition, the "muscle adjacent to the administration site muscle" is also a site that is preferably not affected (pharmacological action) by the composition of an embodiment.

[0044] The compound muscle action potential measurement value of the muscle at the administration site of the composition of one embodiment may be lower than the compound muscle action potential measurement value of the muscle at the administration site when the same dose of an animal protein-containing composition is administered to the same administration site and at the same administration location.

[0045] According to one embodiment of the present invention, there is provided a composition comprising an uncomplexed botulinum toxin as an active ingredient, free of animal protein, for use in a method for treating a disease in a patient in need of such treatment, the method comprising the step of locally administering to a subject in need of such treatment a therapeutically effective amount of a composition of one embodiment, whereby a botulinum toxin composition is provided which has an effect at the site of administration for a longer period of time than botulinum toxin compositions comprising animal protein.

[0046] Needless to say, the portions of this specification that are described regarding the botulinum toxin composition can be equally applied to the use of the botulinum toxin composition in the treatment method using the botulinum toxin composition and in the manufacture of medicines for the treatment of diseases, unless otherwise stated.

[0047] According to one embodiment of the present invention, there is provided a method for administering an animal protein-free botulinum toxin composition to an individual to ameliorate or treat a disease.

[0048] In one embodiment, the use is to improve skin wrinkles, square jaws, pointed chins, blemishes, skin softening, scars, acne, pores, elasticity, or keloids, or to treat facial spasms, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headaches, pruritus ani, or hyperhidrosis by administering to an individual a therapeutically effective amount of a composition comprising the botulinum toxin and a pharma- ceutically acceptable vehicle or excipient.

[0049] According to another aspect of the present disclosure, there is provided a method for improving or treating a disease by administering to an individual a composition comprising the botulinum toxin and a pharma- ceutically acceptable excipient or additive. In one embodiment, the method comprises administering to an individual a composition comprising the botulinum toxin and a pharma- ceutically acceptable excipient or additive as an active ingredient, free of animal protein, for use in improving skin wrinkles, square jaws, pointed chins, scars, skin softening, scars, acne, pores, elasticity, or keloids, or for treating facial spasms, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headaches, pruritus ani, or hyperhidrosis. In one embodiment, skin wrinkles may include frown lines, forehead wrinkles (e.g., horizontal wrinkles on the forehead), wrinkles around the mouth, wrinkles around the eyes (e.g., outer eye wrinkles (fine lines around the eyes), under-eye wrinkles), marionette lines, or wrinkles along the bridge of the nose.

[0050] In one embodiment, the botulinum toxin can be administered in a single or multiple treatment sessions. The dosage can be administered by a single injection or split injections at the injection site. In multiple treatment sessions, the botulinum toxin can be administered at intervals of 1 year or less, 10 months or less, 8 months or less, 6 months or less, 5 months or less, 4 months or less, or 3 months or less. For example, the administration interval can be 3 months or more and 1 year or less, 3 months or more and 6 months or more, or 4 months or more and 6 months or less. In multiple treatment sessions, the administration interval of the botulinum toxin includes a primary treatment and a secondary treatment, and the dosage of the secondary treatment can be less than, greater than, or the same as the dosage of the primary treatment.

[0051] The administration dose, administration time, administration method, administration period or interval of the botulinum toxin can be appropriately selected by a person of ordinary skill in the art depending on the patient's weight, age, sex, health condition, severity of the disease, etc.

[0052] Subjects to which the botulinum toxin or compositions containing same can be administered include, without limitation, humans and animals, such as humans, pigs, dogs, cats, cows, horses, rats, and the like.

[0053] According to one embodiment of the invention there may be provided the use of a botulinum toxin composition according to claim 1, claim 2 or claim 12 in the manufacture of a medicament for improving skin wrinkles, square jaw, pointed chin, blemishes, skin softening, scars, acne, pores, elasticity or keloid conditions or for treating facial spasm, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headaches, pruritus ani or hyperhidrosis.

[0054] According to yet another aspect of the present disclosure, there is provided a method for producing a botulinum toxin composition that exhibits reduced diffusion at a site of administration relative to a botulinum toxin composition that includes an animal protein, comprising administering to an individual a composition comprising the botulinum toxin as an active ingredient and a pharma- ceutically acceptable excipient or additive.

[0055] The present disclosure will be described in more detail below with reference to examples. However, these examples are intended only to explain the present disclosure and are not intended to limit the scope of the present disclosure in any way.

[0056] 1. Diffusion reduction effect of the composition according to one embodiment Example 1: Non-clinical efficacy studies of Coretox and Neuronox in mice Female 5-week-old CD1 (ICR) mice were purchased from Orient Bio, and after acclimatization and quarantine for one week, 6-week-old mice were used for the experiment. Sterilized solid feed for laboratory animals (R40-10 (SAFE (France))) was fed ad libitum, and drinking water was autoclave-sterilized tap water and fed ad libitum. During the acclimatization period, quarantine period, and experimental period, the mice were kept under specific pathogen-free conditions set at a temperature of 23 ± 3 ° C, a relative humidity of 55 ± 15%, a lighting time of 12 hours (8:00 am to 8:00 pm), a ventilation rate of 15 times / hour, and an illuminance of 150 to 300 Lux. This experiment was conducted after review and approval (A-2020-016) by the Medytox Animal Experiment Ethics Committee.

[0057] Test substances were prepared as follows. Coretox (Lot No: NSA20011 (Medytox)) and Neuronox (Lot No: TFAA20024 (Medytox)) were used (Table 1). Sterile saline (Daehan Pharmaceutical Industries) was used as the placebo (placebo group). Each test substance was diluted to a concentration of 60 U / ml using sterile saline.

[0058] [Table 1]

[0059] The day the test substance was administered was designated day 0. The mice were anesthetized using an injectable anesthetic (100 mg / kg ketamine hydrochloride + 10 mg / kg xylazine), and then each test substance listed in Table 2 was administered at 0.2 mL / kg using a Hamilton syringe into the right calf muscle of the mice.

[0060] The evaluation was performed using a compound muscle action potential (CMAP) test method, which measures the action potential of muscles in response to external electrical stimulation. The CMAP was measured at the right calf muscle of each mouse using a Nicolet Viking Quest (Viasys Healthcare, Inc.) device. After anesthetizing with an injectable anesthetic, the hair at the measurement site was removed and the mouse was placed in a prone position. The negative electrode was placed at the sciatic nerve site on the foot side to be measured, and the positive electrode was placed at a site 1 cm away from that site based on the spine. The recording electrode and the reference electrode were placed at the calf muscle site and the Achilles tendon site, respectively, and the ground electrode was placed at the rectus femoris site. The level and duration of the stimulation were set to 7-8 mA and 0.1 ms, and the filter range of the amplifier was set to 2-10K at 60 Hz. When measured under these conditions, the height from the base to the peak of the waveform was converted into data as the CMAP measurement value. Seven days after administration of the test substance, measurements were made on the calf muscle at the administration site and on the calf muscle of the opposite leg.

[0061] Graphpad Prism 7.05 (GraphPad Software Inc., CA, USA) was used for graphical presentation, and SPSS software 25.0 (SPSS Inc., IL, USA) and Excel (2013, MS, USA) were used for statistical analysis. Experimental results were expressed as mean ± standard deviation. Normality tests were performed using the Kolmogorov-Smirnov test. Nonparametric data were statistically analyzed via the Mann-Whitney test, and for parametric data, a two-tailed t-test was performed, and a p-value less than 0.05 was considered statistically significant.

[0062] [Table 2]

[0063] Two botulinum toxin type A products (Coretox, Neuronox) were administered at a dose of 12 U / kg to the right calf muscle of mice, and on the seventh day, CMAP measurements were performed on the administered muscle and the non-administered muscle on the opposite side. As a result, no significant difference was observed in the CMAP value of the administered muscle between the Coretox and Neuronox groups, but the CMAP value of the contralateral muscle was significantly higher in the Coretox group than in the Neuronox group (Figure 1). These results confirmed that the non-albumin formulation of Coretox had a reduced diffusion effect of botulinum toxin compared to the albumin formulation of Neuronox.

[0064] Example 2: Non-clinical efficacy study of different formulations of botulinum toxin type A in rats The following experiment confirmed that the diffusion-reducing effect of such a non-albumin formulation was also observed when a 900 kDa toxin was used.

[0065] Female 6-week-old SD rat mice were purchased from Orient Bio Co., Ltd., and after acclimation and quarantine for one week, 7-week-old rats were used for the experiment. Sterilized solid feed for laboratory animals (R40-10 (SAFE (France))) was fed ad libitum, and drinking water was autoclave-sterilized tap water and fed ad libitum. During the acclimation, quarantine and experimental periods, the mice were kept under specific pathogen-free conditions set at a temperature of 23 ± 3 °C, relative humidity of 55 ± 15%, lighting time of 12 hours (8:00 am to 8:00 pm), ventilation rate of 15 times / hour, and illuminance of 150 to 300 Lux. This study was conducted after review and approval (A-2021-001) by the Medytox Animal Experiment Ethics Committee.

[0066] The test substances were prepared as follows. 100 units of complexed botulinum toxin type A complete products, TFXA21004 (Medytox) and NXA20001 (Medytox), were used (Table 3). Sterile saline (Daehan Pharmaceutical Industries) was used as a placebo (placebo group). Each test substance was diluted to a concentration of 100 U / mL using sterile saline.

[0067] [Table 3]

[0068] The day the test substances were administered was designated as day 0. The rats were anesthetized using an injectable anesthetic (60 mg / kg ketamine hydrochloride + 10 mg / kg xylazine), and then each test substance was administered at 0.02 mL / kg to the right tibialis anterior of the rats according to the group composition (Table 4) using a Hamilton syringe.

[0069] [Table 4]

[0070] Compound muscle action potential (CMAP) test method was used for evaluation. CMAP was measured at the right tibialis anterior (treated muscle) and calf muscle (non-treated muscle) sites of each rat on the 14th day after administration of the test substance, using UltraPro S100 (Natus neurology Inc.) equipment. After anesthetization with an injectable anesthetic, the hair at the measurement site was removed and the rat was placed in a prone position. The positive electrode was placed at the right psoas muscle of the 4th and 5th lumbar vertebrae of the rat, and the negative electrode was placed at the right sciatic nerve based on the 5th and 6th lumbar vertebrae. The distance between the positive and negative electrodes was maintained at 1.5 cm. The recording electrodes were placed at the tibialis anterior and calf muscles, the reference electrode was placed at the Achilles tendon, and the ground electrode was placed at the rectus femoris muscle. The stimulation level and duration were set to 20-30mA, 0.2ms, and the amplifier filter range was set to 2-10K at 60Hz. When measured under these conditions, the height from the baseline to the highest point after the latent period of the waveform was converted into data as CMAP measurement values. The obtained data was statistically processed in the same manner as in Example 1.

[0071] Two different formulations of complexed botulinum toxin type A (TFXA21004 (albumin formulation) and NXA20001 (non-albumin formulation)) were administered at a dose of 2 U / kg to the right tibialis anterior muscle of rats, and CMAP measurements were performed on the right tibialis anterior muscle (treated muscle) and the right calf muscle (non-treated muscle) on the 14th day. As a result, no difference in CMAP value was observed between the two test substances in the right tibialis anterior muscle, but in the right calf muscle (non-treated muscle), a significantly increased CMAP value was observed in the NXA20001-treated group compared to the TFXA21004-treated group (Figure 2). From these results, it was confirmed that the non-animal complexed botulinum toxin type A formulation has an effect of reducing the diffusion of botulinum toxin in adjacent muscles compared to the animal-based formulation.

[0072] Example 3: Non-clinical efficacy study of five botulinum toxin products in mice Female 5-week-old CD1 (ICR) mice were purchased from Orient Bio, and after acclimation and quarantine for one week, 6-week-old mice were used for the experiment. Sterilized solid feed for laboratory animals (R40-10 (SAFE (France))) was fed ad libitum, and drinking water was autoclave-sterilized tap water and fed ad libitum. During the acclimation, quarantine, and experimental periods, the mice were kept under specific pathogen-free conditions set at a temperature of 23 ± 3 °C, relative humidity of 55 ± 15%, lighting time of 12 hours (8:00 am to 8:00 pm), ventilation rate of 15 times / hour, and illuminance of 150 to 300 Lux. This experiment was conducted after review and approval (A-2020-016) by the Medytox Animal Experiment Ethics Committee.

[0073] Test substances were prepared as follows. Coretox (Lot No: NSA20011 (Medytox)), Neuronox (Lot No: TFAA20024 (Medytox)), Innotox (Lot No: D020003 (Medytox)), Xeomin (Lot No: 925559 (Merz)), and Botox (Lot No: C5394C3 (Allergan)) were used (Table 5). Sterile saline (Daehan Pharmaceutical Industries) was used as a placebo (placebo group). Each test substance was diluted to a concentration of 60 U / ml using sterile saline, and Innotox was used as a liquid product.

[0074] [Table 5]

[0075] The day when the test substances were administered was designated as day 0, and the mice were anesthetized using an injectable anesthetic (100 mg / kg ketamine hydrochloride + 10 mg / kg xylazine), and then each test substance was administered into the right calf muscle of the mice using a Hamilton syringe according to Table 6. Coretox, Neuronox, Xeomin, and Botox were administered at 0.2 mL / kg, and Innotox was administered at 0.3 mL / kg. After the primary administration, the secondary and tertiary test substances were prepared in the same manner as the primary administration and administered at the same dose at the same location at 84-day intervals.

[0076] The evaluation was carried out using the digital abduction score (DAS) evaluation method, which visually evaluates the location of muscle paralysis in mice, and the compound muscle action potential (CMAP) test method, which measures the action potential of muscles responding to external electrical stimulation. The DAS values ​​shown in Table 7 indicate the degree of muscle paralysis due to the shape of the toes on the administered side of the mouse, and the CMAP values ​​indicate the degree of direct muscle contraction inhibition indicated by nerve blockade. The DAS recovery period indicates the period when the DAS score returns to 0 after administration of the test substance. The CMAP measurement was carried out in the same manner as in Example 1.

[0077] Graphpad Prism 7.05 (GraphPad Software Inc., CA, USA) was used for graph presentation, and SPSS software 25.0 (SPSS Inc., IL, USA) and Excel (2013, MS, USA) were used for statistical analysis. Experimental results were expressed as mean ± standard deviation. In the DAS graph and CMAP graph, AUC (area under the curve) and AAC (area above the curve) values ​​were calculated using Graphpad Prism software. One-way ANOVA was performed, and Tukey's post-hoc test was performed for intergroup comparison. In the analysis, a p value less than 0.05 was considered to be statistically significant.

[0078] [Table 6]

[0079] [Table 7]

[0080] Five types of botulinum toxin type A products (Coretox, Xeomin, Botox, Neuronox, Innotox) were administered at a dose of 12 U / kg three times at 84-day intervals to the right calf muscle of mice, and DAS evaluation showed that no significant difference was observed in the DAS recovery period after the first administration, but after the second and third administrations, a significant increase in the DAS recovery period was observed in the Coretox and Innotox groups compared to the Xeomin group. In addition, after the third administration, a significant increase in the DAS recovery period was observed in the Coretox group compared to the Botox and Neuronox groups (Table 8). In the DAS graph, after the third administration on the 168th day, all individuals in the Coretox and Innotox groups were observed to recover on the 252nd day, all individuals in the Botox and Neuronox groups were observed to recover on the 231st day, and all individuals in the Xeomin group were observed to recover on the 217th day, with a long duration of action observed in the Coretox and Innotox groups (Figure 3). Similarly, the DAS, an index showing cumulative pharmacological effects over time, AUC After the second and third doses, the DAS of the Coretox, Innotox, and Neuronox groups compared to the Xeomin group was AUCAfter the third injection, the DAS of the Coretox and Innotox groups was significantly higher than that of the Botox group. AUC was observed to be significantly higher (Table 8).

[0081] Similar to the DAS evaluation, the CMAP measurement of the injection site muscle on the 252nd day, which was the final time point after the tertiary injection on the 168th day, showed significantly lower CMAP values ​​in the Coretox and Innotox groups compared to the Xeomin group, demonstrating strong efficacy (Figure 4). AAC As a result of the comparison, after the first administration, the CMAP of the Coretox administration group, Neuronox administration group, and Botox administration group compared to the Xeomin administration group was AAC was observed to be significantly higher, and the CMAP of the Coretox group was significantly higher than that of the Innotox group. AAC After the second dose, the CMAP of the Coretox, Neuronox, Botox, and Innotox groups was significantly higher than that of the Xeomin group. AAC After the third administration, the CMAP of the Coretox group was significantly higher than that of the Xeomin group. AAC was observed to be significantly higher (Table 9). Referring to Figure 5, the CMAP measurement results for the contralateral muscles 6 and 7 days after administration of each botulinum toxin showed that after the second administration, a significant increase in the CMAP values ​​of the contralateral muscles was observed in the Coretox and Innotox groups compared to the Botox and Neuronox groups. Since Xeomin was found to have weaker efficacy compared to the four types of botulinum toxins (see Figure 4), the significant increase in the CMAP values ​​of the contralateral muscles in the Xeomin group is considered to be due to its weaker efficacy compared to the four types of botulinum toxin products, rather than due to a diffusion inhibitory effect.

[0082] Based on these results, the effects of three repeated administrations of five types of botulinum toxin type A products were compared in mice, and the results showed that non-albumin formulations of botulinum toxins (Coretox, Innotox) had stronger efficacy, longer duration of action, and reduced diffusion compared to albumin formulations of botulinum toxins (Xeomin, Botox, Neuronox).

[0083] [Table 8]

[0084] a, b and c: Different superscripts indicate statistically significant differences (one-way ANOVA, Tukey's post-hoc test).

[0085] [Table 9]

[0086] a, b and c: Different superscripts indicate statistically significant differences (one-way ANOVA, Tukey's post-hoc test).

Claims

1. 1. A composition free of animal protein and comprising a botulinum toxin as an active ingredient for use in a method for treating a disease in a patient in need of treatment, The method includes the step of locally administering to a subject in need of treatment a therapeutically effective amount of the composition; A botulinum toxin composition that exhibits reduced diffusion at the site of administration relative to botulinum toxin compositions that include animal proteins.

2. 2. The botulinum toxin composition of claim 1, wherein the botulinum toxin is an uncomplexed botulinum toxin.

3. 3. The botulinum toxin composition of claim 1 or 2, wherein the composition has an effect at the site of administration for a longer period of time than a botulinum toxin composition comprising an animal protein.

4. 3. The botulinum toxin composition of claim 1 or 2, wherein the composition is a lyophilized composition.

5. 5. The botulinum toxin composition of claim 4, wherein the lyophilized composition comprises one or more components selected from the group consisting of botulinum toxin, polysorbate, methionine; and sugars, sugar alcohols, and ionic compounds.

6. 3. The botulinum toxin composition of claim 1 or 2, wherein the animal protein-free botulinum toxin composition is a liquid composition.

7. 6. The botulinum toxin composition of claim 5, wherein the liquid composition comprises a botulinum toxin, a polysorbate, and methionine.

8. 8. The botulinum toxin composition of claim 1, wherein the composition is for improving skin wrinkles, square jaw, pointed chin, wounds, skin softening, scars, acne, pores, elasticity or keloid conditions, or for treating facial spasm, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headache, pruritus ani or hyperhidrosis.

9. 4. The botulinum toxin composition of claim 1 or 3, wherein the reduced diffusion effect, or the effect for an extended period of time, occurs upon two or more repeated administrations.

10. The composition of claim 1 or 2, wherein the compound muscle action potential measurement value of the administration site muscle and an adjacent muscle of the composition is higher than the compound muscle action potential measurement value of the administration site muscle and an adjacent muscle of the composition when the same dose of an animal protein-containing composition is administered to the same administration site and the same administration location.

11. The composition according to any one of claims 1 to 3, wherein the compound muscle action potential measurement value of the administration site muscle of the composition is lower than the compound muscle action potential measurement value of the administration site muscle when the same dose of an animal protein-containing composition is administered to the same administration site and the same administration position.

12. 1. A composition free of animal protein and comprising as an active ingredient an uncomplexed botulinum toxin for use in a method for treating a disease in a patient in need of treatment, The method includes the step of locally administering to a subject in need of treatment a therapeutically effective amount of the composition; A botulinum toxin composition that has a prolonged duration of effect at the site of administration than botulinum toxin compositions that include animal proteins.

13. 13. Use of the botulinum toxin composition of any one of claims 1, 2 and 12 in the manufacture of a medicament for improving skin wrinkles, square jaw, pointed chin, wounds, skin softening, scars, acne, pores, elasticity or keloid conditions, or for treating facial spasm, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headaches, pruritus ani or hyperhidrosis.

14. 17. A method for improving skin wrinkles, square jaw, pointed chin, blemishes, skin softening, scars, acne, pores, elasticity or keloid conditions or for treating facial spasms, blepharospasm, torticollis, blepharospasm, cervical dystonia, mid-pharyngeal dystonia, spasmodic dysphonia, migraine headaches, pruritus ani or hyperhidrosis, comprising the step of administering to an individual a therapeutically effective amount of a botulinum toxin composition of any one of claims 1, 2 and 12.

15. 15. The method of claim 14, wherein the reduced diffusion effect occurs upon two or more repeated administrations.

Citation Information

Patent Citations

  • A pharmaceutical liquid composition with improved stability of botulinum toxin.

    JP2010532784A

  • Botulinum toxin freeze-dried preparation

    JP2014509644A

  • Long-term sustained action of a new botulinum toxin preparation

    JP2016540785A

  • Botulinum toxin preparations for injection and methods of using them having a long duration of therapeutic or cosmetic effect

    JP2018531984A